Financial Toxicity From Generic Specialty Drug Use-Reference-Cited by-同舟云学术

Financial Toxicity From Generic Specialty Drug Use

Published:2021-02-01 Issue:2 Volume:7 Page:175
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Fischer Katrina A.¹,Miller Robert E.²,Glaspy John A.¹

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles

2. Independent researcher, San Mateo, California

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2773117/jamaoncology_fischer_2020_vp_200034_1613590922.79872.pdf

Reference7 articles.

1. Sending the wrong price signal: why do some brand-name drugs cost Medicare beneficiaries less than generics?;Dusetzina;Health Aff (Millwood),2019

2. Generic price competition for specialty drugs: too little, too late?;Cole;Health Aff (Millwood),2018

3. Possible insufficiency of generic price competition to contain prices for orally administered anticancer therapies.;Cole;JAMA Intern Med,2017

4. Conrad? R, Lutter? R. Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices.? US Food and Drug Administration. December 2019. Accessed September 11, 2020. https://www.fda.gov/media/133509/download

5. Truven Health Analytics. Red Book: a comprehensive, consistent drug pricing resource. Accessed April 24, 2020. https://www.ibm.com/products/micromedex-red-book

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacy Assistance Programs for Oral Anticancer Drugs: A Narrative Review;JCO Oncology Practice;2024-01-19

2. Access to Financial Assistance Programs and Their Impact on Overall Spending on Oral Anticancer Medications at an Integrated Specialty Pharmacy;JCO Oncology Practice;2024-01-04

3. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues;Drug Discovery Today;2022-01

4. Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies;Neurotherapeutics;2021-07

5. Errors in Box;JAMA Oncology;2021-02-01